about
High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson diseaseNeuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent PerspectivesDopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeysTranslating principles of neural plasticity into research on speech motor control recovery and rehabilitation.The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 1.Neuroimaging and therapeutics in movement disorders.Human gene therapy and imaging in neurological diseases.Late-stage α-synuclein accumulation in TNWT-61 mouse model of Parkinson's disease detected by diffusion kurtosis imaging.Animal models of neurodegenerative disease: insights from in vivo imaging studies.Assessment of the progression of Parkinson's disease: a metabolic network approach.MR spectroscopy, functional MRI, and diffusion-tensor imaging in the aging brain: a conceptual review.Imaging genetics approach to Parkinson's disease and its correlation with clinical score.Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease.CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease.Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseasesThe PRIPS study: screening battery for subjects at risk for Parkinson's disease.Unbiased approaches to biomarker discovery in neurodegenerative diseasesNonhuman primate models of Parkinson's disease.Neuroprotection trials in Parkinson's disease: systematic review.Recent progress of imaging agents for Parkinson's disease.Changes in network activity with the progression of Parkinson's disease.Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility.Feasibility of Computed Tomography-Guided Methods for Spatial Normalization of Dopamine Transporter Positron Emission Tomography Image.Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transportersRecent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders.Expert testimony at the Food and Drug Administration: who wants the truth?Fully Automated Quantification of the Striatal Uptake Ratio of [(99m)Tc]-TRODAT with SPECT Imaging: Evaluation of the Diagnostic Performance in Parkinson's Disease and the Temporal Regression of Striatal Tracer Uptake.Gene therapy for Parkinson's disease using recombinant adeno-associated viral vectors.Low nigrostriatal reserve for motor parkinsonism in nonhuman primates.Heterogeneity of Monosymptomatic Resting Tremor in a Prospective Study: Clinical Features, Electrophysiological Test, and Dopamine Transporter Positron Emission Tomography.Molecular functional imaging in personalized clinical oncology: The road less traveled.Biomedical imaging research opportunities workshop IV: a white paper.Molecular imaging in hereditary forms of parkinsonism.Validation of nigrostriatal positron emission tomography measures: critical limits.Why hasn't neuroprotection worked in Parkinson's disease?Role of DAT-SPECT in the diagnostic work up of parkinsonism.Update on the use of pramipexole in the treatment of Parkinson's disease.A perspective on the current issues in the diagnosis of Parkinson's disease.Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy.
P2860
Q22065275-730A1A97-D641-40F2-BC74-F97CD6570B48Q26747508-FE2033FB-492F-4193-98E5-01E4229BA89CQ27316473-C7925CB9-74DE-49BA-8CA6-62352B23914BQ28754738-29531D77-143C-40C1-9630-5117C9271DAFQ30829363-7418AC11-BE45-4B24-84E2-618060EA6B93Q30989947-168C4899-5E30-4C4A-9517-7DA66DF32C7CQ31023442-3C0C0AE4-3A63-4B1C-860F-4D015BEE3DA6Q31032932-3A3EA295-10D6-4BA0-B7A9-6B573D476947Q31105537-7D8D54DC-50FC-4E4B-98EB-FF03227B5EC5Q31130371-2747905B-DC60-435F-B864-859F9835BA43Q33277156-923F47DA-5573-4C9E-B66E-D9CB2A3CB28FQ33587357-A72ABDB1-CF74-4257-88E6-B42736BB6A12Q33602588-0C74BF19-35D4-43EB-AAC5-5AD1D6DEA84CQ33994583-22202892-E297-42D1-9061-35ADBD277065Q34027880-088EF36E-28EA-45F5-9C7C-288076C22639Q34071942-AE44FA56-E259-4921-A1B5-28C5D9AE40C7Q34361343-1DB6EEFB-6838-4383-B693-D406FFBC15F7Q34625918-DDF3246C-10DB-427F-9E1F-2222084C3E25Q34665820-7D0CFBFF-CF8A-4138-A829-D189DCC588D9Q34913056-58EEF1C9-7672-4E7F-8F66-B3E77E8F5927Q35595426-DDF6748E-2234-4F44-8F80-066169F33F89Q35679748-8DE8B13C-0839-4D48-AA1A-2144D92BA607Q35683286-6EE63CED-A54F-4FBE-9742-650BABD4E998Q35683827-BF4FA6E9-97CD-4AFC-A0BD-284E706D2766Q35891436-99DAD756-4A32-4529-825E-92E2CA5A760EQ35910290-D857243E-D699-4468-9BED-A49DFC9821BBQ35927182-2A2BFCFF-BF73-45E7-982F-84B6C52B159EQ36022062-F8A4A269-6D36-42B0-A911-48383DA53F20Q36150495-EFB0ACC7-B3F3-4C34-995F-9C9BDBA472D7Q36236735-367DBD0B-B3EB-45C6-BBA3-426DF9FF8E52Q36523068-8DDA8D36-0D3C-4649-801E-5073E0484F2FQ36696339-5EF59E6D-4DDF-47AE-A267-AD0D05C76137Q36771634-56851F27-384B-4F60-B5F2-A4A63C761E29Q36771898-5320A577-1CDA-4F05-9F81-003AF3173D1FQ36780857-D8FDC454-ABC8-4B1E-A031-A7A73F33734CQ36811113-A9410C12-711A-48D1-B760-40867E1D7FF5Q36814559-5463CA8F-B3D2-4F52-BB07-5CA20A348EB6Q36842189-C1292122-204F-4AF4-A9C3-198E0A0AA93BQ36842617-73748D14-7C56-4ABE-A017-EE80FB07BED2Q37114685-ED560E36-1512-44F5-A87C-357990B22B1B
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The role of radiotracer imaging in Parkinson disease.
@ast
The role of radiotracer imaging in Parkinson disease.
@en
type
label
The role of radiotracer imaging in Parkinson disease.
@ast
The role of radiotracer imaging in Parkinson disease.
@en
prefLabel
The role of radiotracer imaging in Parkinson disease.
@ast
The role of radiotracer imaging in Parkinson disease.
@en
P2093
P50
P1433
P1476
The role of radiotracer imaging in Parkinson disease.
@en
P2093
Ahlskog JE
Holloway R
P304
P356
10.1212/01.WNL.0000149403.14458.7F
P407
P577
2005-01-01T00:00:00Z